

TECHNICAL DATA SHEET

Recombinant Human sIL-4R α (Carrier-free)

Catalog Number: 21-9242

RPx-Pro™ Recombinant Protein PRODUCT INFORMATION

CONTENTS

Recombinant Human sIL-4R α (Carrier-free)

DESCRIPTION

IL-4R alpha is a Type I transmembrane protein belonging to the class I cytokine receptor family and is a component of two different receptor complexes. When associated with the common gamma chain, which is required for signaling, it binds IL-4 with higher affinity. When complexed with IL-13R alpha I, interaction with both IL-4 and IL-13 is enabled. Through JAK/STAT signal transduction pathways, cell-specific responses including Th2 differentiation, mucosal immunity, allergic inflammation and IgE production result. The soluble form of IL-4R alpha, generated through proteolysis in the human, retains biologic activity and is able to antagonize IL-4.

MOLECULAR MASS

Recombinant Human sIL-4R α corresponds to the entire extracellular domain of IL-4R α and consists of 209 amino acids.

AMINO ACID SEQUENCE

GNMKVLQEPT CVSDYMSIST CEWKMNPGPTN CSTEELRLLYQ LVFLLSEAHT CIPENNGGAG CVCHLLMDDV VSADNYTLDL WAGQQLLWKG
SFKPSEHVKP RAPGNLTVHT NVSDTLTLLTW SNPYPPDNYL YNHLTYAVNI WSENDPADFR IYNVTYLEPS LRIAASLTKS GISYRARVRA WAQCYNTTWS
EWSPSTKWHN SYREPFEQH

SOURCE

CHO cells

APPLICATIONS

Bioassay

PURITY

≥95 %

STORAGE

-20°C

PROTEIN CONTENT

Verified by HPLC and/or SDS-PAGE gel.

ENDOTOXIN LEVEL

Endotoxin level is <0.1 ng/μg of protein (<1 EU/μg).

AUTHENTICITY

Verified by N-terminal and Mass Spectrometry analyses (when applicable).

CROSS REACTIVITY

N/A

BIOACTIVITY

The expected ED₅₀ of ≤ 5.0 ng/ml, corresponding to a specific activity of ≥ 2 x 10⁵ units/mg, is measured by determining the ability to inhibit the IL-4 dependent proliferation of human TF-1 cells while in the presence of 0.5 ng/ml IL-4.

RESEARCH AREAS

Immune System, Apoptosis, Cancer, Allergy, Inflammation, Receptors, Differentiation, Proliferation, Stem Cells, Cell Culture, Transplantation

RECONSTITUTION

See Certificate of Analysis (COA) for lot specific reconstitution information.

REFERENCES

Maliszewski CR, Sato TA, Davison B, Jacobs CA, Finkelman FD and Fanslow WC. 1994. Proc Soc Exp Biol Med. 206(3): 233-7. Kruse S, Forster J, Kuehr J and Deichmann KA. 1999. Int Immunol. 11(12): 1965-1970. Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S, Arai K and Sugamura K. 1993. Science. 262(5141): 1874-1877. Wills-Karp M and Finkelman FD. 2008. Sci Signal. 1(51): pe55. Jung T, Schrader N, Hellwig M, Enssle KH and Neumann C. 1999. Int Arch Allergy Immunol. 199(1): 23-30.

Citations are provided as a resource for additional applications that have not been validated by Tonbo Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.

Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Tonbo Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Tonbo Biosciences, Tonbo Biosciences Logo and all other trademarks are the property of Tonbo Biotechnologies Corporation. © 2013 Tonbo Biosciences.